Literature DB >> 19094163

High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?

Jan-Willem C Alffenaar, Tessa de Vos, Donald R A Uges, Simon M G J Daenen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19094163      PMCID： PMC2670385          DOI： 10.1111/j.1365-2125.2008.03315.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

2.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

Review 3.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

Authors:  Alexander Imhof; Dominik J Schaer; Urs Schanz; Urs Schwarz
Journal:  Swiss Med Wkly       Date:  2006-11-11       Impact factor: 2.193

7.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

Authors:  R Hyland; B C Jones; D A Smith
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

Review 8.  Therapeutic drug monitoring of voriconazole.

Authors:  Roger J M Brüggemann; J Peter Donnelly; Rob E Aarnoutse; Adilia Warris; Nicole M A Blijlevens; Johan W Mouton; Paul E Verweij; David M Burger
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

9.  The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.

Authors:  Lynn Purkins; Nolan Wood; Katie Greenhalgh; Malcolm D Eve; Stuart D Oliver; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 10.  Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring.

Authors:  D R Dufour; J A Lott; F S Nolte; D R Gretch; R S Koff; L B Seeff
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327
View more
  6 in total

1.  Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage.

Authors:  Jan-Willem C Alffenaar; Kim C M van der Elst; Donald R A Uges; Jos G W Kosterink; Simon M G J Daenen
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

2.  Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database.

Authors:  Zhi-Xuan Zhou; Xue-Dong Yin; Yu Zhang; Qi-Hui Shao; Xin-Yu Mao; Wen-Juan Hu; Yun-Lin Shen; Bin Zhao; Zhi-Ling Li
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

3.  Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Authors:  J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

4.  Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.

Authors:  Kim C M van der Elst; Lambert F R Span; Kai van Hateren; Karin M Vermeulen; Tjip S van der Werf; Ben Greijdanus; Jos G W Kosterink; Donald R A Uges; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

5.  Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.

Authors:  Xiao-Bin Lin; Zi-Wei Li; Miao Yan; Bi-Kui Zhang; Wu Liang; Feng Wang; Ping Xu; Da-Xiong Xiang; Xu-Biao Xie; Shao-Jie Yu; Gong-Bin Lan; Feng-Hua Peng
Journal:  Br J Clin Pharmacol       Date:  2018-05-06       Impact factor: 4.335

6.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.